Zhang Lihua, Li Rong, He Junyi, Yang Qiuping, Wu Yanan, Huang Jingshan, Wu Bin
Department of Geriatric Endocrinology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, China.
Department of Nephrology, First People's Hospital of Yunnan Province, Kunming, Yunnan 650032, China.
Methods. 2017 Jul 15;124:46-56. doi: 10.1016/j.ymeth.2017.05.023. Epub 2017 May 31.
Diabetic kidney disease (DKD) is a serious disease that presents a major health problem worldwide. There is a desperate need to explore novel biomarkers to further facilitate the early diagnosis and effective treatment in DKD patients, thus preventing them from developing end-stage renal disease (ESRD). However, most regulation mechanisms at the genetic level in DKD still remain unclear. In this paper, we describe our innovative methodologies that integrate biological, computational, and statistical approaches to investigate important roles performed by regulations among microRNAs (miRs), long non-coding RNAs (lncRNAs), and messenger RNAs (mRNAs) in DKD. We conducted fully transparent, rigorously designed experiments. Our robust and reproducible results identified hsa-miR-223-3p as a candidate novel biomarker performing important roles in DKD disease process.
糖尿病肾病(DKD)是一种严重疾病,在全球范围内构成重大健康问题。迫切需要探索新的生物标志物,以进一步促进DKD患者的早期诊断和有效治疗,从而防止他们发展为终末期肾病(ESRD)。然而,DKD在基因水平上的大多数调控机制仍不清楚。在本文中,我们描述了我们的创新方法,该方法整合了生物学、计算和统计方法,以研究微小RNA(miRs)、长链非编码RNA(lncRNAs)和信使RNA(mRNAs)之间的调控在DKD中所起的重要作用。我们进行了完全透明、设计严谨的实验。我们可靠且可重复的结果确定hsa-miR-223-3p为在DKD疾病过程中发挥重要作用的候选新型生物标志物。